Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint

Dow Jones04:37

By Kelly Cloonan

Praxis Precision Medicines said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial.

The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications.

The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline.

However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said.

"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile," Chief Executive Marcio Souza said.

Praxis is developing vormatrigine as a once-daily, oral treatment for adult focal onset seizures and generalized epilepsy. Vormatrigine is a small molecule that targets the hyperexcitable state of sodium-channels in the brain, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 01, 2026 16:37 ET (20:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640962558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640962558","market":"fut","top_or_hot":-1,"title":"Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial. \n</p>\n<p>\n  The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications. \n</p>\n<p>\n  The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline. \n</p>\n<p>\n  However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said. \n</p>\n<p>\n  \"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile,\" Chief Executive Marcio Souza said. \n</p>\n<p>\n  Praxis is developing vormatrigine as a once-daily, oral treatment for adult focal onset seizures and generalized epilepsy. Vormatrigine is a small molecule that targets the hyperexcitable state of sodium-channels in the brain, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 16:37 ET (20:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-02 04:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial. \n</p>\n<p>\n  The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications. \n</p>\n<p>\n  The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline. \n</p>\n<p>\n  However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said. \n</p>\n<p>\n  \"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile,\" Chief Executive Marcio Souza said. \n</p>\n<p>\n  Praxis is developing vormatrigine as a once-daily, oral treatment for adult focal onset seizures and generalized epilepsy. Vormatrigine is a small molecule that targets the hyperexcitable state of sodium-channels in the brain, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 16:37 ET (20:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640962558","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640962558","pubTimestamp":1780346220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Praxis Precision Medicines said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial.The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications.The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline.However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said.\"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile,\" Chief Executive Marcio ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","PRAX":"Praxis Precision Medicines, Inc.","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4139":"生物科技","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Praxis Precision Medicines的癫痫治疗未能达到试验的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nPraxis Precision Medicines said vormatrigine, a treatment it is developing for certain seizures and epilepsy, did not meet its primary endpoint in a recent trial. \n\n\n  The biopharmaceutical company said Monday it is now pausing enrollment in the study to reassess the program and consider modifications. \n\n\n  The Phase 2/3 trial evaluated the safety and efficacy of vormatrigine in adults with focal onset seizures who are concurrently taking at least one but no more than three anti-seizure medications. The study's primary endpoint was the percent change in monthly seizure frequency from baseline. \n\n\n  However, the study met a secondary measure for a 50% response rate. Additionally, seizure reduction was more pronounced during the second half of the study, when patients received a higher dose, the company said. \n\n\n  \"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile,\" Chief Executive Marcio Souza said. \n\n\n  Praxis is developing vormatrigine as a once-daily, oral treatment for adult focal onset seizures and generalized epilepsy. Vormatrigine is a small molecule that targets the hyperexcitable state of sodium-channels in the brain, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 16:37 ET (20:37 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640962558","isCrawlerRequest":true}